Klin Onkol 2008; 21(Suppl 1): 207-209.
In this paper we show an example of use the detection of chromosomal abnormalities using modifi ed fl uorescence in situ hybridization (FISH) and following searching for the impact of chromosomal abnormalities to successful treatment of multiple myeloma patients. In our group of 74 patients treated either by thalidomide (Myrin) or by bortezomib (Velcade) was only observed statistically
signifi cantly worse TTP in patients treated by thalidomide and having gain of CKS1B. According to our data the new drugs overcome the impact of negative cytogenetic prognostic markers with exception of patients with gain 1q21 treated by thalidomide.
